Piracetam

There are long-standing unmet clinical needs in the rehabilitation treatment of central nervous system degenerative diseases and sequelae of brain injury. Piracetam, as a cyclic derivative of γ-aminobutyric acid, is one of the nootropic drugs first applied in clinical practice. Its mechanism of action is to activate adenylate kinase, increase the ATP/ADP ratio in the brain, promote intracerebral metabolism and acetylcholine synthesis, and enhance nerve excitation conduction. It can improve memory loss and mild to moderate brain dysfunction caused by acute and chronic cerebrovascular diseases, brain trauma, toxic encephalopathy, etc. It is also applicable to the intervention of children's mental retardation, covering people with central function impairment of all age groups.

According to public market data, the overall domestic market size of piracetam in 2023 was approximately RMB 1.27 billion, with a compound growth rate of 4.2% in the past three years. The demand side has maintained steady growth driven by the popularization of elderly cognitive impairment screening and rehabilitation medical policies. The competitive landscape is dominated by generic drugs, with more than 30 domestic manufacturers. Oral dosage forms have been included in the national centralized procurement, with the price reduction of selected products exceeding 80%. The market of public medical institutions is concentrated on head production capacity, while there is still a stable supply gap in the out-of-hospital retail and API export markets.

The original research enterprise of piracetam is UCB, and the original research trade name is Nootropil. Its core compound patent expired worldwide in 1992. At present, the dosage forms of the original research approved in China include tablets (0.4g, 0.8g) and injections (20ml:4g, 5ml:1g), which have been included in the *Catalogue of Reference Preparations for Chemical Drugs* issued by the National Medical Products Administration. According to the domestic API registration platform, as of now, 17 enterprises have obtained A-status registration numbers for piracetam APIs, and corresponding preparations of multiple dosage forms such as oral and injection have been approved for marketing domestically. (Data as of June 2025, please refer to the official website of CDE for the latest information)

CATO provides a full set of impurity reference standards for piracetam API, covering all types of research needs such as process impurities and degradation impurities. Most products are available in stock. Orders for in-stock products placed before 16:00 can be shipped on the same day. All reference standards meet the requirements of multiple regulatory systems such as the Chinese Pharmacopoeia and FDA, and can provide stable reference standard support for pharmaceutical enterprises in consistency evaluation, quality research and registration declaration.